<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03590613</url>
  </required_header>
  <id_info>
    <org_study_id>205037</org_study_id>
    <nct_id>NCT03590613</nct_id>
  </id_info>
  <brief_title>Phase I Study of GSK2982772 in Japanese Healthy Male Participants</brief_title>
  <official_title>A Single-centre, Randomized, Double-blind, Dose-ascending, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral TID Doses (One Day) of GSK2982772 in Japanese Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study plans to enroll approximately 12 subjects. The main objective of the study is to
      assess the safety, tolerability and pharmacokinetics (PK) of the three times a day (TID),
      dosing of GSK2982772, in Japanese healthy male subjects. The study will comprise of four
      study periods each at least 7 days in duration with subjects in-house for 4 nights (through
      72 hrs after the first dose). During each treatment period (TP), subjects will be admitted to
      the unit the day before dosing and will be discharged after completion of the 72 hours
      post-dose assessments. There will be a washout of atleast 7-days between the TP doses for
      each individual, post which there will be 7-days follow-up. The dose range proposed in this
      study is based on a low starting dose, which will be escalated to the highest dose that is
      intended for the Phase 2b dose range study. The decision to proceed to the next dose-level,
      of GSK2982772 within the study will be made by principal investigator and GSK Medical Monitor
      per each dosing periods. The study duration is approximately 22 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 19, 2018</start_date>
  <completion_date type="Actual">September 26, 2018</completion_date>
  <primary_completion_date type="Actual">September 21, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Study will comprise of four TPs, each of at least 7 days in duration with subjects in-house for 4 nights (through 72 hours after the first dose). During each TP, subjects will be admitted to the unit, day before dosing and will be discharged after completion of 72 hours post-dose assessments. dose will be administered TID, in an ascending manner. Every individual subject will receive placebo and GSK2982772 (60, 120,240 mg TID) as per assigned sequence. For TID dosing, GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hour (the second dosing) and 14 hour (the third dosing) on Day 1 in each period. On Day 1, subjects will fast 8hour overnight prior to first dose. breakfast will be served approximately 2hour after first dose. Lunch and dinner will be served between 2 to 3hour prior to second and third doses, respectively. A washout of atleast 7-days between the TP doses for each individual subject.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>It is a double-blinded study, where the subjects, investigators and the site-staff will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>From the day of first dose to 39 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement. Safety population comprised of all participants who have received at least one dose of study treatment. This population was used for the safety analyses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Clinical Chemistry Parameters</measure>
    <time_frame>Baseline (Day -1) and at 72 hours at each treatment period</time_frame>
    <description>Blood samples were collected for the analysis of clinical chemistry parameters including: glucose, calcium, cholesterol, chloride, high density lipoprotein (HDL) cholesterol, potassium, low density lipoprotein (LDL) cholesterol, phosphate, sodium, triglycerides and urea. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein</measure>
    <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
    <description>Blood samples were collected for the analysis of clinical chemistry parameters including: albumin and protein. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatinine Kinase (CK), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrognase (LDH)</measure>
    <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
    <description>Blood samples were collected for the analysis of clinical chemistry parameters including: ALP, ALT, AST, CK, GGT and LDH. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Clinical Chemistry Parameter: Amylase</measure>
    <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
    <description>Blood samples were collected for the analysis of clinical chemistry parameter: amylase. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Clinical Chemistry Parameters: Direct Bilirubin, Bilirubin, Creatinine and Urate (Uric Acid)</measure>
    <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
    <description>Blood samples were collected for the analysis of clinical chemistry parameters:direct bilirubin, bilirubin, creatinine and urate. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Clinical Chemistry Parameter: C-reactive Protein (CRP) of TID Doses for One Day of GSK2982772</measure>
    <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
    <description>Blood samples were collected for the analysis of clinical chemistry parameter: CRP. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Hematocrit</measure>
    <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
    <description>Blood samples were collected for the analysis of hematology parameter: hematocrit. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Hemoglobin</measure>
    <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
    <description>Blood samples were collected for the analysis of hematology parameter: hemoglobin. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Hemoglobin (MCH)</measure>
    <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
    <description>Blood samples were collected for the analysis of hematology parameter: erythrocyte MCH. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume (MCV)</measure>
    <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
    <description>Blood samples were collected for the analysis of hematology parameter: erythrocyte MCV. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Erythrocytes</measure>
    <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
    <description>Blood samples were collected for the analysis of hematology parameter: erythrocytes. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Parameter: Reticulocytes/Erythrocytes</measure>
    <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
    <description>Blood samples were collected for the analysis of hematology parameter: percentage reticulocytes. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Parameters: Platelets and Leukocytes of TID Doses for One Day of GSK2982772</measure>
    <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
    <description>Blood samples were collected for the analysis of hematology parameters including platelet count and leukocytes. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematology Parameters of TID Doses for One Day of GSK2982772</measure>
    <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
    <description>Blood samples were collected for the analysis of hematology parameters including neutrophils/leukocytes, lymphocytes/leukocytes, monocytes/leukocytes, eosinophils/leukocytes and basophils/leukocytes. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Urine Potential of Hydrogen (pH)</measure>
    <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
    <description>Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0). Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Urine Specific Gravity</measure>
    <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
    <description>Urine samples were collected for analysis of urine specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. The urinary specific gravity measurement is a routine part of urinalysis. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Urinalysis Results by Dipstick Method</measure>
    <time_frame>At 72 hours of each Treatment Period</time_frame>
    <description>Urine samples were collected to assess urine bilirubin, urine glucose, urine ketones, urine occult blood, urine protein and urine urobilinogen by dipstick test. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameter of urine bilirubin, urine occult blood, urine glucose, urine ketones, urine protein and urine urobilinogen can be read as negative (-) and trace (+-) indicating proportional concentrations in the urine sample.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Electrocardiogram (ECG) Finding: Mean Heart Rate</measure>
    <time_frame>Baseline (Day -1) and at 2, 7, 14, 24, 48 and 72 hours at each Treatment Period</time_frame>
    <description>Full 12-lead ECGs were recorded in participant using an automated ECG machine. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in ECG Findings of TID Doses for One Day of GSK2982772</measure>
    <time_frame>Baseline (Day -1) and at 2, 7, 14, 24, 48 and 72 hours at each Treatment Period</time_frame>
    <description>Full 12-lead ECGs were recorded in participants using an automated ECG machine and measured PR, QRS, QT and QTcF intervals. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Not Clinically Significant Cardiac Telemetry</measure>
    <time_frame>Up to 24 hours at each Treatment Period</time_frame>
    <description>Continuous cardiac telemetry was performed and number of participants with abnormal clinically significant and not clinically significant values are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</measure>
    <time_frame>Baseline (Day -1) and at 2, 7, 14, 24, 48 and 72 hours at each treatment period</time_frame>
    <description>Blood pressure of participants were measured at indicated time points in supine position after 5 minutes rest. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Pulse Rate of TID Doses for One Day of GSK2982772</measure>
    <time_frame>Baseline (Day -1) and at 2, 7, 14, 24, 48 and 72 hours at each Treatment Period</time_frame>
    <description>Pulse rate of participants were measured at indicated time points in supine position after 5 minutes rest. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Body Temperature of TID Doses for One Day of GSK2982772</measure>
    <time_frame>Baseline (Day -1) and at 2, 7, 14, 24, 48 and 72 hours at each Treatment Period</time_frame>
    <description>Temperature of participants were measured at indicated time points in supine position after 5 minutes rest. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormal Neurological Examinations of TID Doses for One Day of GSK2982772</measure>
    <time_frame>Baseline (Day -1) and at 2, 7, 14, 24, 48 and 72 hours at each Treatment Period</time_frame>
    <description>Neurological examinations including: mental status, gait, balance, coordination, cranial nerves, motor power, reflexes, and sensory system (light touch and pain) were assessed in participants specified time points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Drug Concentration Versus Time Curve Over 24 Hours (AUC[0-24]) and AUC Over Each Dose Interval of TID Doses for One Day of GSK2982772</measure>
    <time_frame>Pre-dose, 20 and 40 minutes, 1, 1.5, 2, 3, 5, 7 hours, 7 hours 20 minutes, 7 hours 40 minutes, 8, 8.5, 9, 10, 12, 14 hours, 14 hours 20 minutes, 14 hours 40 minutes, 15, 15.5, 16, 17, 19, 22 and 24 hours post-dose at each Treatment Period</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24) and AUC over each dose: AUC(0-7), AUC (7-14) and AUC (14-24) after the administration of TID doses of GSK2982772. Pharmacokinetic analysis was conducted using standard non-compartmental methods. All participants in the safety population for whom a pharmacokinetic sample has been obtained and analyzed was included in the pharmacokinetic population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) and Observed Trough Drug Plasma Concentrations Following Each TID Doses for One Day of GSK2982772</measure>
    <time_frame>Pre-dose,20 and 40 minutes, 1, 1.5, 2, 3, 5, 7 hours,7 hours 20 minutes,7 hours 40 minutes,8, 8.5, 9, 10, 12, 14 hours,14 hours 20 minutes,14 hours40 minutes, 15, 15.5, 16, 17, 19, 22, 24, 28, 32, 36, 48, 60 and 72 hours post-dose at each Treatment Period</time_frame>
    <description>Blood samples were collected from participants at indicated time points and analyzed for Cmax and observed trough drug plasma concentrations: C0, C7, C14 and C24 after the administration of TID doses of GSK2982772.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half Life (t1/2) After the Third TID Dose for One Day of GSK2982772</measure>
    <time_frame>Pre-dose,20 and 40 minutes, 1, 1.5, 2, 3, 5, 7 hours,7 hours 20 minutes,7 hours 40 minutes,8, 8.5, 9, 10, 12, 14 hours,14 hours 20 minutes,14 hours40 minutes, 15, 15.5, 16, 17, 19, 22, 24, 28, 32, 36, 48, 60 and 72 hours post-dose at each Treatment Period</time_frame>
    <description>Blood samples were collected from participants at indicated time points and t1/2 was analyzed after the administration of third TID dose of GSK2982772.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Plasma Drug Concentration (Tmax) of Each TID Doses for One Day of GSK2982772</measure>
    <time_frame>Pre-dose,20 and 40 minutes, 1, 1.5, 2, 3, 5, 7 hours,7 hours 20 minutes,7 hours 40 minutes,8, 8.5, 9, 10, 12, 14 hours,14 hours 20 minutes,14 hours40 minutes, 15, 15.5, 16, 17, 19, 22, 24, 28, 32, 36, 48, 60 and 72 hours post-dose at each Treatment Period</time_frame>
    <description>Blood samples were collected from participants at indicated time points and Tmax was analyzed after the administration of TID doses of GSK2982772.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Autoimmune Diseases</condition>
  <arm_group>
    <arm_group_label>Sequence 1: Placebo TID then 60 TID then 120 TID then 240 TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The eligible subjects in this arm will receive placebo TID in TP1, GSK2982772 60 mg TID in TP2, GSK2982772 120mg TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2: 60 TID then Placebo TID then 120 TID then 240 TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, placebo TID in TP2, GSK2982772 120mg TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3: 60 TID then 120 TID then Placebo TID then 240 TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, GSK2982772 120mg TID in TP2, placebo TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4: 60 TID then 120 TID then 240 TID then Placebo TID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The eligible subjects in this arm will receive GSK2982772 60 mg TID in TP1, GSK2982772 120mg TID in TP2, GSK2982772 240 mg TID in TP3 and placebo TID in TP4. GSK2982772 or placebo will be administered at 0 hour (the first dosing), 7 hours (the second dosing) and 14 hours (the third dosing) on Day 1 in each TP. Subjects will fast overnight for 8 hours before first dose. Each TP will be followed by a washout period of at least 7 days, for each subject.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2982772</intervention_name>
    <description>GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route</description>
    <arm_group_label>Sequence 1: Placebo TID then 60 TID then 120 TID then 240 TID</arm_group_label>
    <arm_group_label>Sequence 2: 60 TID then Placebo TID then 120 TID then 240 TID</arm_group_label>
    <arm_group_label>Sequence 3: 60 TID then 120 TID then Placebo TID then 240 TID</arm_group_label>
    <arm_group_label>Sequence 4: 60 TID then 120 TID then 240 TID then Placebo TID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route.</description>
    <arm_group_label>Sequence 1: Placebo TID then 60 TID then 120 TID then 240 TID</arm_group_label>
    <arm_group_label>Sequence 2: 60 TID then Placebo TID then 120 TID then 240 TID</arm_group_label>
    <arm_group_label>Sequence 3: 60 TID then 120 TID then Placebo TID then 240 TID</arm_group_label>
    <arm_group_label>Sequence 4: 60 TID then 120 TID then 240 TID then Placebo TID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be 20 to 64 years of age inclusive, at the time of signing the informed
             consent.

          -  Healthy as determined by the Investigators based on a medical evaluation including
             medical history, physical examination, neurological examination, laboratory tests, and
             ECG. A subject with a clinical abnormality or laboratory parameter(s) which is/are not
             specifically listed in the inclusion or exclusion criteria, outside the reference
             range for the population being studied may be included only if the Investigators in
             consultation with the GSK Medical Monitor agree and document that the finding is
             unlikely to introduce additional risk factors and will not interfere with the study
             procedures.

          -  Body weight &gt;= 50 kilogram (kg) and body mass index (BMI) within the range 18.5-24.9
             kg/meter square (inclusive).

          -  Japanese male subjects must agree to use contraception as detailed in protocol during
             the treatment period and until follow up visit.

          -  Capable of giving informed consent as described in the protocol.

        Exclusion Criteria:

          -  History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,
             endocrine, hematological, or neurological disorders capable of significantly altering
             the absorption, metabolism, or elimination of drugs; constituting a risk when taking
             the study treatment; or interfering with the interpretation of data.

          -  Abnormal blood pressure as determined by the investigators.

          -  Symptomatic herpes zoster within 3 months prior to screening.

          -  Evidence of active or latent Tuberculosis (TB) as documented by medical history and
             examination, chest X-rays (anterior and lateral), and TB testing (T Spot. TB)

          -  ALT &gt;1.5 times upper limit of normal (ULN).

          -  Bilirubin &gt;1.5 times ULN (isolated bilirubin &gt;1.5 times ULN is acceptable if bilirubin
             is fractionated and direct bilirubin &lt;35%)

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).

          -  History of active infections within 14 days of first receiving study medication.

          -  Corrected Q-T interval (QTc) obtained using the Fridericia's formula (QTcF) &gt; 450
             millisecond.

          -  History or diagnosis of obstructive sleep apnoea, or a significant respiratory
             disorder. Childhood asthma that was fully resolved is permitted.

          -  History of active Suicidal Ideation Behavior within the past 6 months or any history
             of attempted suicide in a subject's lifetime.

          -  History or current evidence of febrile seizures, epilepsy, convulsions, significant
             head injury, or other significant neurologic conditions.

          -  Past or intended use of over-the-counter or prescription medication including herbal
             medications within 14 days prior to dosing; live vaccine(s) within 1 month prior to
             screening, or plans to receive such vaccines during the study.

          -  History of donation of blood or blood products &gt;= 400 mL within 3 months or &gt;= 200 mL
             within 1 month prior to screening.

          -  Exposure to more than 4 new chemical entities within 12 months prior to the first
             dosing day.

          -  The subject has participated in a other clinical study or other medical research
             within 4 months prior to the first dosing day in the current study.

          -  Subject is positive Serological test for syphilis Rapid Plasma Reagin [RPR] and
             Treponema pallidum [TP]), Tuberculosis, human immunodeficiency virus (HIV)
             Antigen/Antibody, Hepatitis B surface antigen (HbsAg), Hepatitis C virus (HCV)
             antibody, or Human T-cell leukemia virus type 1 (HTLV-1) antibody at screening.

          -  Positive pre-study drug screen.

          -  Regular use of known drugs of abuse.

          -  Regular alcohol consumption within 6 months prior to the study defined as: for an
             average weekly intake of &gt; 14 units for males. One unit is equivalent to 350 mL of
             beer, 150 mL of wine or 45 mL of 80 proof distilled spirits.

          -  Smoking or history or regular use of tobacco- or nicotine-containing products within 6
             months prior to screening.

          -  Sensitivity to any of the study treatments, or components thereof, or drug or other
             allergy that, in the opinion of the investigators or GSK Medical Monitor,
             contraindicates participation in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 6, 2018</study_first_submitted>
  <study_first_submitted_qc>July 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2018</study_first_posted>
  <results_first_submitted>August 8, 2019</results_first_submitted>
  <results_first_submitted_qc>September 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 17, 2019</results_first_posted>
  <last_update_submitted>September 16, 2019</last_update_submitted>
  <last_update_submitted_qc>September 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sentinel-dosing</keyword>
  <keyword>GSK2982772</keyword>
  <keyword>Japnese</keyword>
  <keyword>Dose-ascending</keyword>
  <keyword>Crossover</keyword>
  <keyword>Healthy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available, within 6 months of publishing the results of the primary endpoints of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided, after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided, for an initial period of 12 months but an extension can be granted, when justified for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 11, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT03590613/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT03590613/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a 4-way crossover, single-center, randomized, double-blind, dose-ascending, placebo (PBO)-controlled study to evaluate the safety, tolerability, and pharmacokinetics of oral TID doses (thrice a day) of GSK2982772 in healthy male Japanese participants</recruitment_details>
      <pre_assignment_details>A total of 13 healthy male Japanese participants were enrolled in the study to receive GSK2982772 and PBO from a single center in Japan</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Sequence A: PBO TID /60mg TID /120mg TID /240mg TID</title>
          <description>Participants in this arm received PBO TID in treatment period (TP) 1, GSK2982772 60 milligram (mg) TID in TP2, GSK2982772 120 mg TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 and placebo was administered at 0 hour (starting dose), 7 hours (second dose) and 14 hours (third dose) on Day 1 in each TP. Participants had fasted overnight for 8 hours before first dose. Each TP was followed by a washout period of at least 7 days, for each participant.</description>
        </group>
        <group group_id="P2">
          <title>Treatment Sequence B: 60mg TID /PBO TID /120mg TID /240mg TID</title>
          <description>Participants in this arm received GSK2982772 60 mg TID in TP1, PBO TID in TP2, GSK2982772 120mg TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 and placebo was administered at 0 hour (starting dose), 7 hours (second dose) and 14 hours (third dose) on Day 1 in each TP. Participants had fasted overnight for 8 hours before first dose. Each TP was followed by a washout period of at least 7 days, for each participant.</description>
        </group>
        <group group_id="P3">
          <title>Treatment Sequence C: 60mg TID/ 120mg TID/ PBO TID/ 240mg TID</title>
          <description>Participants in this arm received GSK2982772 60 mg TID in TP1, GSK2982772 120mg TID in TP2, PBO TID in TP3 and GSK2982772 240 mg TID in TP4. GSK2982772 and placebo was administered at 0 hour (starting dose), 7 hours (second dose) and 14 hours (third dose) on Day 1 in each TP. Participants had fasted overnight for 8 hours before first dose. Each TP was followed by a washout period of at least 7 days, for each participant.</description>
        </group>
        <group group_id="P4">
          <title>Treatment Sequence D: 60mg TID /120mg TID /240mg TID /PBO TID</title>
          <description>Participants in this arm received GSK2982772 60 mg TID in TP1, GSK2982772 120mg TID in TP2, GSK2982772 240 mg TID in TP3 and PBO TID in TP4. GSK2982772 and placebo was administered at 0 hour (starting dose), 7 hours (second dose) and 14 hours (third dose) on Day 1 in each TP. Participants had fasted overnight for 8 hours before first dose. Each TP was followed by a washout period of at least 7 days, for each participant.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1, 4 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 1, Wash-out, at Least 3 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2, 4 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4">One additional participant was enrolled in Period 2.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2, Wash-out, at Least 3 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3, 4 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3,Wash-out, at Least 3 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4, 4 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All study participants received GSK2982772 and PBO in four treatment sequences (A,B,C &amp;D) at 0 hour (starting dose), 7 hours (second dose) and 14 hours (third dose) on Day 1 in each TP.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.2" spread="7.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian-Japanese/East Asian/South East AsianHeritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement. Safety population comprised of all participants who have received at least one dose of study treatment. This population was used for the safety analyses.</description>
        <time_frame>From the day of first dose to 39 days</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement. Safety population comprised of all participants who have received at least one dose of study treatment. This population was used for the safety analyses.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Clinical Chemistry Parameters</title>
        <description>Blood samples were collected for the analysis of clinical chemistry parameters including: glucose, calcium, cholesterol, chloride, high density lipoprotein (HDL) cholesterol, potassium, low density lipoprotein (LDL) cholesterol, phosphate, sodium, triglycerides and urea. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
        <time_frame>Baseline (Day -1) and at 72 hours at each treatment period</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Chemistry Parameters</title>
          <description>Blood samples were collected for the analysis of clinical chemistry parameters including: glucose, calcium, cholesterol, chloride, high density lipoprotein (HDL) cholesterol, potassium, low density lipoprotein (LDL) cholesterol, phosphate, sodium, triglycerides and urea. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
          <population>Safety Population.</population>
          <units>Millimoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.240543" spread="0.1426732"/>
                    <measurement group_id="O2" value="-0.282176" spread="0.2348638"/>
                    <measurement group_id="O3" value="-0.240543" spread="0.2902134"/>
                    <measurement group_id="O4" value="-0.226666" spread="0.2554319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.016633" spread="0.0683974"/>
                    <measurement group_id="O2" value="0.058217" spread="0.0341987"/>
                    <measurement group_id="O3" value="-0.022871" spread="0.0732901"/>
                    <measurement group_id="O4" value="-0.004158" spread="0.1036024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000000" spread="0.2092177"/>
                    <measurement group_id="O2" value="0.073270" spread="0.2657498"/>
                    <measurement group_id="O3" value="0.015085" spread="0.3458001"/>
                    <measurement group_id="O4" value="-0.049565" spread="0.3560217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.38"/>
                    <measurement group_id="O2" value="0.2" spread="2.25"/>
                    <measurement group_id="O3" value="1.2" spread="1.59"/>
                    <measurement group_id="O4" value="0.6" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.071115" spread="0.1097839"/>
                    <measurement group_id="O2" value="-0.034480" spread="0.1070976"/>
                    <measurement group_id="O3" value="-0.084045" spread="0.1046815"/>
                    <measurement group_id="O4" value="-0.116370" spread="0.0578247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.156"/>
                    <measurement group_id="O2" value="0.01" spread="0.329"/>
                    <measurement group_id="O3" value="0.03" spread="0.501"/>
                    <measurement group_id="O4" value="-0.07" spread="0.419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.036635" spread="0.1670318"/>
                    <measurement group_id="O2" value="0.101285" spread="0.1673953"/>
                    <measurement group_id="O3" value="0.017240" spread="0.2663211"/>
                    <measurement group_id="O4" value="-0.043100" spread="0.1926790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.064580" spread="0.0963795"/>
                    <measurement group_id="O2" value="0.053817" spread="0.1210793"/>
                    <measurement group_id="O3" value="0.002691" spread="0.1155721"/>
                    <measurement group_id="O4" value="0.018836" spread="0.1366196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.78"/>
                    <measurement group_id="O2" value="1.3" spread="1.72"/>
                    <measurement group_id="O3" value="0.9" spread="1.93"/>
                    <measurement group_id="O4" value="1.4" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19398" spread="0.117614"/>
                    <measurement group_id="O2" value="0.12618" spread="0.153495"/>
                    <measurement group_id="O3" value="0.13372" spread="0.286674"/>
                    <measurement group_id="O4" value="0.13466" spread="0.368074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09223" spread="0.656241"/>
                    <measurement group_id="O2" value="-0.21123" spread="0.796454"/>
                    <measurement group_id="O3" value="-0.03273" spread="0.309530"/>
                    <measurement group_id="O4" value="-0.31238" spread="0.705860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein</title>
        <description>Blood samples were collected for the analysis of clinical chemistry parameters including: albumin and protein. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
        <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein</title>
          <description>Blood samples were collected for the analysis of clinical chemistry parameters including: albumin and protein. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
          <population>Safety Population.</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="2.64"/>
                    <measurement group_id="O2" value="-0.4" spread="1.62"/>
                    <measurement group_id="O3" value="-1.6" spread="2.47"/>
                    <measurement group_id="O4" value="-2.5" spread="3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="3.96"/>
                    <measurement group_id="O2" value="0.8" spread="2.12"/>
                    <measurement group_id="O3" value="-2.1" spread="3.70"/>
                    <measurement group_id="O4" value="-2.3" spread="4.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatinine Kinase (CK), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrognase (LDH)</title>
        <description>Blood samples were collected for the analysis of clinical chemistry parameters including: ALP, ALT, AST, CK, GGT and LDH. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
        <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Chemistry Parameters: Alkaline Phosphate (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Creatinine Kinase (CK), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrognase (LDH)</title>
          <description>Blood samples were collected for the analysis of clinical chemistry parameters including: ALP, ALT, AST, CK, GGT and LDH. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
          <population>Safety Population.</population>
          <units>International units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.1" spread="17.32"/>
                    <measurement group_id="O2" value="-6.8" spread="12.63"/>
                    <measurement group_id="O3" value="-10.6" spread="14.41"/>
                    <measurement group_id="O4" value="-9.0" spread="14.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="3.66"/>
                    <measurement group_id="O2" value="0.5" spread="2.47"/>
                    <measurement group_id="O3" value="-2.2" spread="3.33"/>
                    <measurement group_id="O4" value="-1.3" spread="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="2.68"/>
                    <measurement group_id="O2" value="0.3" spread="1.76"/>
                    <measurement group_id="O3" value="-1.8" spread="3.28"/>
                    <measurement group_id="O4" value="-2.5" spread="6.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.1" spread="14.95"/>
                    <measurement group_id="O2" value="-34.2" spread="21.70"/>
                    <measurement group_id="O3" value="-51.7" spread="48.61"/>
                    <measurement group_id="O4" value="-39.6" spread="32.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.67"/>
                    <measurement group_id="O2" value="-0.5" spread="1.62"/>
                    <measurement group_id="O3" value="-1.8" spread="2.93"/>
                    <measurement group_id="O4" value="-1.5" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDH</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.7" spread="9.76"/>
                    <measurement group_id="O2" value="-11.3" spread="8.01"/>
                    <measurement group_id="O3" value="-21.6" spread="14.92"/>
                    <measurement group_id="O4" value="-21.3" spread="10.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Clinical Chemistry Parameter: Amylase</title>
        <description>Blood samples were collected for the analysis of clinical chemistry parameter: amylase. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
        <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Chemistry Parameter: Amylase</title>
          <description>Blood samples were collected for the analysis of clinical chemistry parameter: amylase. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
          <population>Safety Population</population>
          <units>Units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="10.56"/>
                    <measurement group_id="O2" value="9.1" spread="6.26"/>
                    <measurement group_id="O3" value="4.4" spread="9.34"/>
                    <measurement group_id="O4" value="1.1" spread="8.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Clinical Chemistry Parameters: Direct Bilirubin, Bilirubin, Creatinine and Urate (Uric Acid)</title>
        <description>Blood samples were collected for the analysis of clinical chemistry parameters:direct bilirubin, bilirubin, creatinine and urate. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
        <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Chemistry Parameters: Direct Bilirubin, Bilirubin, Creatinine and Urate (Uric Acid)</title>
          <description>Blood samples were collected for the analysis of clinical chemistry parameters:direct bilirubin, bilirubin, creatinine and urate. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
          <population>Safety Population.</population>
          <units>Micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Direct bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.428" spread="1.0629"/>
                    <measurement group_id="O2" value="0.285" spread="0.9873"/>
                    <measurement group_id="O3" value="0.143" spread="1.1432"/>
                    <measurement group_id="O4" value="-0.285" spread="0.9873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.850" spread="4.7998"/>
                    <measurement group_id="O2" value="2.850" spread="4.7998"/>
                    <measurement group_id="O3" value="1.568" spread="5.9441"/>
                    <measurement group_id="O4" value="-0.428" spread="4.0679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8840" spread="7.47252"/>
                    <measurement group_id="O2" value="0.5157" spread="4.46730"/>
                    <measurement group_id="O3" value="0.6630" spread="5.25184"/>
                    <measurement group_id="O4" value="1.6943" spread="3.97949"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8093" spread="29.82999"/>
                    <measurement group_id="O2" value="9.4177" spread="23.16992"/>
                    <measurement group_id="O3" value="17.8440" spread="17.93389"/>
                    <measurement group_id="O4" value="8.4263" spread="27.95138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Clinical Chemistry Parameter: C-reactive Protein (CRP) of TID Doses for One Day of GSK2982772</title>
        <description>Blood samples were collected for the analysis of clinical chemistry parameter: CRP. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
        <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Chemistry Parameter: C-reactive Protein (CRP) of TID Doses for One Day of GSK2982772</title>
          <description>Blood samples were collected for the analysis of clinical chemistry parameter: CRP. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
          <population>Safety Population.</population>
          <units>Milligrams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.078" spread="0.2290"/>
                    <measurement group_id="O2" value="-0.016" spread="0.0268"/>
                    <measurement group_id="O3" value="-0.050" spread="0.1028"/>
                    <measurement group_id="O4" value="0.126" spread="0.5390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Parameter: Hematocrit</title>
        <description>Blood samples were collected for the analysis of hematology parameter: hematocrit. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
        <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Hematocrit</title>
          <description>Blood samples were collected for the analysis of hematology parameter: hematocrit. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
          <population>Safety Population.</population>
          <units>Percentage of red blood cells in blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0039" spread="0.01946"/>
                    <measurement group_id="O2" value="0.0075" spread="0.01332"/>
                    <measurement group_id="O3" value="-0.0048" spread="0.01434"/>
                    <measurement group_id="O4" value="-0.0043" spread="0.02172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Parameter: Hemoglobin</title>
        <description>Blood samples were collected for the analysis of hematology parameter: hemoglobin. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
        <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Hemoglobin</title>
          <description>Blood samples were collected for the analysis of hematology parameter: hemoglobin. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
          <population>Safety Population.</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="6.01"/>
                    <measurement group_id="O2" value="4.6" spread="5.74"/>
                    <measurement group_id="O3" value="-1.4" spread="5.57"/>
                    <measurement group_id="O4" value="-0.4" spread="8.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Hemoglobin (MCH)</title>
        <description>Blood samples were collected for the analysis of hematology parameter: erythrocyte MCH. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
        <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Hemoglobin (MCH)</title>
          <description>Blood samples were collected for the analysis of hematology parameter: erythrocyte MCH. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
          <population>Safety Population.</population>
          <units>Picograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.269"/>
                    <measurement group_id="O2" value="0.17" spread="0.299"/>
                    <measurement group_id="O3" value="0.10" spread="0.234"/>
                    <measurement group_id="O4" value="0.15" spread="0.261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume (MCV)</title>
        <description>Blood samples were collected for the analysis of hematology parameter: erythrocyte MCV. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
        <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Erythrocyte Mean Corpuscular Volume (MCV)</title>
          <description>Blood samples were collected for the analysis of hematology parameter: erythrocyte MCV. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
          <population>Safety Population.</population>
          <units>Femtoliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.90"/>
                    <measurement group_id="O2" value="-0.7" spread="0.89"/>
                    <measurement group_id="O3" value="-0.2" spread="0.39"/>
                    <measurement group_id="O4" value="-0.4" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Parameter: Erythrocytes</title>
        <description>Blood samples were collected for the analysis of hematology parameter: erythrocytes. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
        <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Erythrocytes</title>
          <description>Blood samples were collected for the analysis of hematology parameter: erythrocytes. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
          <population>Safety Population.</population>
          <units>10^12 cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.058" spread="0.2387"/>
                    <measurement group_id="O2" value="0.126" spread="0.1583"/>
                    <measurement group_id="O3" value="-0.059" spread="0.1624"/>
                    <measurement group_id="O4" value="-0.035" spread="0.2731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Parameter: Reticulocytes/Erythrocytes</title>
        <description>Blood samples were collected for the analysis of hematology parameter: percentage reticulocytes. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
        <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameter: Reticulocytes/Erythrocytes</title>
          <description>Blood samples were collected for the analysis of hematology parameter: percentage reticulocytes. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
          <population>Safety Population.</population>
          <units>Ratio of Reticulocytes to Erythrocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0002" spread="0.00221"/>
                    <measurement group_id="O2" value="0.0001" spread="0.00188"/>
                    <measurement group_id="O3" value="-0.0008" spread="0.00242"/>
                    <measurement group_id="O4" value="-0.0003" spread="0.00201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Parameters: Platelets and Leukocytes of TID Doses for One Day of GSK2982772</title>
        <description>Blood samples were collected for the analysis of hematology parameters including platelet count and leukocytes. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
        <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameters: Platelets and Leukocytes of TID Doses for One Day of GSK2982772</title>
          <description>Blood samples were collected for the analysis of hematology parameters including platelet count and leukocytes. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
          <population>Safety Population.</population>
          <units>10^9 cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Platelets</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="21.35"/>
                    <measurement group_id="O2" value="2.5" spread="26.12"/>
                    <measurement group_id="O3" value="-12.8" spread="23.03"/>
                    <measurement group_id="O4" value="-6.4" spread="18.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.927"/>
                    <measurement group_id="O2" value="-0.05" spread="0.992"/>
                    <measurement group_id="O3" value="-0.42" spread="1.214"/>
                    <measurement group_id="O4" value="-0.62" spread="0.860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematology Parameters of TID Doses for One Day of GSK2982772</title>
        <description>Blood samples were collected for the analysis of hematology parameters including neutrophils/leukocytes, lymphocytes/leukocytes, monocytes/leukocytes, eosinophils/leukocytes and basophils/leukocytes. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
        <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology Parameters of TID Doses for One Day of GSK2982772</title>
          <description>Blood samples were collected for the analysis of hematology parameters including neutrophils/leukocytes, lymphocytes/leukocytes, monocytes/leukocytes, eosinophils/leukocytes and basophils/leukocytes. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
          <population>Safety Population.</population>
          <units>Percentage of cells in leukocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Neutrophils/Leukocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="4.656"/>
                    <measurement group_id="O2" value="-0.55" spread="4.356"/>
                    <measurement group_id="O3" value="-0.75" spread="5.841"/>
                    <measurement group_id="O4" value="-1.57" spread="8.363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes/Leukocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.13" spread="1.598"/>
                    <measurement group_id="O2" value="-0.24" spread="1.019"/>
                    <measurement group_id="O3" value="-0.01" spread="1.176"/>
                    <measurement group_id="O4" value="-0.48" spread="1.532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes/Leukocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread="4.206"/>
                    <measurement group_id="O2" value="1.02" spread="4.329"/>
                    <measurement group_id="O3" value="1.49" spread="4.847"/>
                    <measurement group_id="O4" value="2.29" spread="8.349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils/Leukocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="0.666"/>
                    <measurement group_id="O2" value="-0.22" spread="1.335"/>
                    <measurement group_id="O3" value="-0.66" spread="1.377"/>
                    <measurement group_id="O4" value="-0.27" spread="0.537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils/Leukocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.180"/>
                    <measurement group_id="O2" value="-0.01" spread="0.090"/>
                    <measurement group_id="O3" value="-0.08" spread="0.129"/>
                    <measurement group_id="O4" value="0.02" spread="0.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Urine Potential of Hydrogen (pH)</title>
        <description>Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0). Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
        <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urine Potential of Hydrogen (pH)</title>
          <description>Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0). Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
          <population>Safety Population.</population>
          <units>pH</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.569"/>
                    <measurement group_id="O2" value="0.42" spread="0.515"/>
                    <measurement group_id="O3" value="0.42" spread="0.515"/>
                    <measurement group_id="O4" value="-0.17" spread="0.537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Urine Specific Gravity</title>
        <description>Urine samples were collected for analysis of urine specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. The urinary specific gravity measurement is a routine part of urinalysis. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
        <time_frame>Baseline (Day -1) and at 72 hours at each Treatment Period</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urine Specific Gravity</title>
          <description>Urine samples were collected for analysis of urine specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The concentration of the excreted molecules determines the urine's specific gravity. The urinary specific gravity measurement is a routine part of urinalysis. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
          <population>Safety Population.</population>
          <units>Ratio of urine density to water density</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0093" spread="0.00702"/>
                    <measurement group_id="O2" value="0.0042" spread="0.00780"/>
                    <measurement group_id="O3" value="0.0068" spread="0.00631"/>
                    <measurement group_id="O4" value="0.0036" spread="0.00825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Urinalysis Results by Dipstick Method</title>
        <description>Urine samples were collected to assess urine bilirubin, urine glucose, urine ketones, urine occult blood, urine protein and urine urobilinogen by dipstick test. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameter of urine bilirubin, urine occult blood, urine glucose, urine ketones, urine protein and urine urobilinogen can be read as negative (-) and trace (+-) indicating proportional concentrations in the urine sample.</description>
        <time_frame>At 72 hours of each Treatment Period</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Urinalysis Results by Dipstick Method</title>
          <description>Urine samples were collected to assess urine bilirubin, urine glucose, urine ketones, urine occult blood, urine protein and urine urobilinogen by dipstick test. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameter of urine bilirubin, urine occult blood, urine glucose, urine ketones, urine protein and urine urobilinogen can be read as negative (-) and trace (+-) indicating proportional concentrations in the urine sample.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bilirubin, 72 hours, negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 72 hours, negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketones, 72 hours, negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult Blood, 72 hours, negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, 72 hours, negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urobilinogen, 72 hours, trace</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Electrocardiogram (ECG) Finding: Mean Heart Rate</title>
        <description>Full 12-lead ECGs were recorded in participant using an automated ECG machine. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
        <time_frame>Baseline (Day -1) and at 2, 7, 14, 24, 48 and 72 hours at each Treatment Period</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Electrocardiogram (ECG) Finding: Mean Heart Rate</title>
          <description>Full 12-lead ECGs were recorded in participant using an automated ECG machine. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
          <population>Safety Population.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="5.20"/>
                    <measurement group_id="O2" value="2.9" spread="4.54"/>
                    <measurement group_id="O3" value="0.6" spread="3.78"/>
                    <measurement group_id="O4" value="2.0" spread="5.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" spread="5.21"/>
                    <measurement group_id="O2" value="9.6" spread="4.72"/>
                    <measurement group_id="O3" value="9.0" spread="5.53"/>
                    <measurement group_id="O4" value="10.8" spread="7.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="3.18"/>
                    <measurement group_id="O2" value="7.3" spread="4.20"/>
                    <measurement group_id="O3" value="7.7" spread="5.35"/>
                    <measurement group_id="O4" value="8.3" spread="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="4.31"/>
                    <measurement group_id="O2" value="2.3" spread="4.03"/>
                    <measurement group_id="O3" value="2.1" spread="6.79"/>
                    <measurement group_id="O4" value="1.8" spread="4.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="3.99"/>
                    <measurement group_id="O2" value="3.7" spread="3.31"/>
                    <measurement group_id="O3" value="1.3" spread="6.96"/>
                    <measurement group_id="O4" value="2.3" spread="7.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="5.57"/>
                    <measurement group_id="O2" value="5.9" spread="3.20"/>
                    <measurement group_id="O3" value="3.7" spread="6.05"/>
                    <measurement group_id="O4" value="8.3" spread="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in ECG Findings of TID Doses for One Day of GSK2982772</title>
        <description>Full 12-lead ECGs were recorded in participants using an automated ECG machine and measured PR, QRS, QT and QTcF intervals. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
        <time_frame>Baseline (Day -1) and at 2, 7, 14, 24, 48 and 72 hours at each Treatment Period</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ECG Findings of TID Doses for One Day of GSK2982772</title>
          <description>Full 12-lead ECGs were recorded in participants using an automated ECG machine and measured PR, QRS, QT and QTcF intervals. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
          <population>Safety Population.</population>
          <units>Milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR interval, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="8.22"/>
                    <measurement group_id="O2" value="-2.3" spread="7.62"/>
                    <measurement group_id="O3" value="0.5" spread="8.36"/>
                    <measurement group_id="O4" value="-4.0" spread="7.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval, 7 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.5" spread="13.70"/>
                    <measurement group_id="O2" value="-8.3" spread="7.95"/>
                    <measurement group_id="O3" value="-3.8" spread="11.77"/>
                    <measurement group_id="O4" value="-7.0" spread="10.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval, 14 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.5" spread="9.95"/>
                    <measurement group_id="O2" value="-0.8" spread="11.92"/>
                    <measurement group_id="O3" value="-0.2" spread="10.77"/>
                    <measurement group_id="O4" value="-4.2" spread="11.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="7.26"/>
                    <measurement group_id="O2" value="-0.2" spread="8.07"/>
                    <measurement group_id="O3" value="1.7" spread="9.18"/>
                    <measurement group_id="O4" value="1.5" spread="13.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="13.75"/>
                    <measurement group_id="O2" value="1.0" spread="9.89"/>
                    <measurement group_id="O3" value="2.8" spread="11.98"/>
                    <measurement group_id="O4" value="3.7" spread="7.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval, 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="15.92"/>
                    <measurement group_id="O2" value="1.2" spread="8.20"/>
                    <measurement group_id="O3" value="2.0" spread="13.43"/>
                    <measurement group_id="O4" value="4.8" spread="13.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="6.60"/>
                    <measurement group_id="O2" value="-2.7" spread="7.69"/>
                    <measurement group_id="O3" value="-2.2" spread="7.16"/>
                    <measurement group_id="O4" value="0.3" spread="4.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration, 7 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="6.95"/>
                    <measurement group_id="O2" value="-0.5" spread="4.52"/>
                    <measurement group_id="O3" value="-0.5" spread="6.39"/>
                    <measurement group_id="O4" value="1.7" spread="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration, 14 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="8.40"/>
                    <measurement group_id="O2" value="0.8" spread="1.59"/>
                    <measurement group_id="O3" value="0.3" spread="5.52"/>
                    <measurement group_id="O4" value="1.5" spread="7.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="5.14"/>
                    <measurement group_id="O2" value="0.7" spread="3.34"/>
                    <measurement group_id="O3" value="-1.3" spread="7.74"/>
                    <measurement group_id="O4" value="0.7" spread="5.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="6.12"/>
                    <measurement group_id="O2" value="-1.3" spread="5.28"/>
                    <measurement group_id="O3" value="-0.2" spread="10.50"/>
                    <measurement group_id="O4" value="-2.5" spread="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration, 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="4.47"/>
                    <measurement group_id="O2" value="0.2" spread="5.62"/>
                    <measurement group_id="O3" value="1.0" spread="8.33"/>
                    <measurement group_id="O4" value="0.3" spread="4.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="13.56"/>
                    <measurement group_id="O2" value="-3.2" spread="22.94"/>
                    <measurement group_id="O3" value="-9.8" spread="20.69"/>
                    <measurement group_id="O4" value="-4.7" spread="17.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval, 7 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.7" spread="18.79"/>
                    <measurement group_id="O2" value="-29.7" spread="15.06"/>
                    <measurement group_id="O3" value="-22.2" spread="22.33"/>
                    <measurement group_id="O4" value="-31.3" spread="24.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval, 14 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.5" spread="17.35"/>
                    <measurement group_id="O2" value="-21.3" spread="17.55"/>
                    <measurement group_id="O3" value="-20.0" spread="20.47"/>
                    <measurement group_id="O4" value="-23.5" spread="20.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" spread="13.59"/>
                    <measurement group_id="O2" value="0.7" spread="14.95"/>
                    <measurement group_id="O3" value="-13.5" spread="16.65"/>
                    <measurement group_id="O4" value="-6.7" spread="13.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="9.55"/>
                    <measurement group_id="O2" value="-7.3" spread="10.39"/>
                    <measurement group_id="O3" value="-15.2" spread="20.85"/>
                    <measurement group_id="O4" value="-15.7" spread="17.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval, 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.0" spread="17.20"/>
                    <measurement group_id="O2" value="-11.8" spread="13.42"/>
                    <measurement group_id="O3" value="-14.7" spread="20.44"/>
                    <measurement group_id="O4" value="-23.3" spread="12.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="16.40"/>
                    <measurement group_id="O2" value="4.0" spread="19.41"/>
                    <measurement group_id="O3" value="-7.1" spread="18.60"/>
                    <measurement group_id="O4" value="0.6" spread="17.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval, 7 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="15.02"/>
                    <measurement group_id="O2" value="-6.7" spread="15.07"/>
                    <measurement group_id="O3" value="-1.4" spread="16.59"/>
                    <measurement group_id="O4" value="-7.2" spread="14.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval, 14 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="16.50"/>
                    <measurement group_id="O2" value="-3.8" spread="12.75"/>
                    <measurement group_id="O3" value="-1.4" spread="13.94"/>
                    <measurement group_id="O4" value="-4.8" spread="15.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="14.44"/>
                    <measurement group_id="O2" value="7.8" spread="15.82"/>
                    <measurement group_id="O3" value="-7.8" spread="19.60"/>
                    <measurement group_id="O4" value="-1.8" spread="9.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="13.55"/>
                    <measurement group_id="O2" value="1.9" spread="7.18"/>
                    <measurement group_id="O3" value="-11.3" spread="12.20"/>
                    <measurement group_id="O4" value="-10.0" spread="16.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval, 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="12.92"/>
                    <measurement group_id="O2" value="2.6" spread="11.37"/>
                    <measurement group_id="O3" value="-4.8" spread="13.30"/>
                    <measurement group_id="O4" value="-4.5" spread="12.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Not Clinically Significant Cardiac Telemetry</title>
        <description>Continuous cardiac telemetry was performed and number of participants with abnormal clinically significant and not clinically significant values are presented.</description>
        <time_frame>Up to 24 hours at each Treatment Period</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Not Clinically Significant Cardiac Telemetry</title>
          <description>Continuous cardiac telemetry was performed and number of participants with abnormal clinically significant and not clinically significant values are presented.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal-not clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal-clinically significant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</title>
        <description>Blood pressure of participants were measured at indicated time points in supine position after 5 minutes rest. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
        <time_frame>Baseline (Day -1) and at 2, 7, 14, 24, 48 and 72 hours at each treatment period</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)</title>
          <description>Blood pressure of participants were measured at indicated time points in supine position after 5 minutes rest. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
          <population>Safety Population.</population>
          <units>Millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="5.13"/>
                    <measurement group_id="O2" value="-2.5" spread="7.22"/>
                    <measurement group_id="O3" value="-1.9" spread="5.73"/>
                    <measurement group_id="O4" value="-2.2" spread="8.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 7 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="6.75"/>
                    <measurement group_id="O2" value="-7.0" spread="8.12"/>
                    <measurement group_id="O3" value="-8.2" spread="8.33"/>
                    <measurement group_id="O4" value="-5.9" spread="8.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 14 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="5.16"/>
                    <measurement group_id="O2" value="-5.3" spread="8.29"/>
                    <measurement group_id="O3" value="-6.9" spread="5.88"/>
                    <measurement group_id="O4" value="-4.3" spread="8.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="6.15"/>
                    <measurement group_id="O2" value="0.3" spread="6.41"/>
                    <measurement group_id="O3" value="-4.0" spread="5.24"/>
                    <measurement group_id="O4" value="-2.4" spread="10.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="6.88"/>
                    <measurement group_id="O2" value="1.3" spread="5.83"/>
                    <measurement group_id="O3" value="-0.3" spread="4.69"/>
                    <measurement group_id="O4" value="0.5" spread="9.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="5.25"/>
                    <measurement group_id="O2" value="0.3" spread="6.66"/>
                    <measurement group_id="O3" value="-0.1" spread="7.18"/>
                    <measurement group_id="O4" value="2.8" spread="10.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="6.85"/>
                    <measurement group_id="O2" value="0.4" spread="7.55"/>
                    <measurement group_id="O3" value="2.4" spread="4.10"/>
                    <measurement group_id="O4" value="0.6" spread="5.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 7 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="8.99"/>
                    <measurement group_id="O2" value="2.5" spread="6.65"/>
                    <measurement group_id="O3" value="-0.7" spread="8.15"/>
                    <measurement group_id="O4" value="1.3" spread="6.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 14 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="5.76"/>
                    <measurement group_id="O2" value="1.0" spread="6.06"/>
                    <measurement group_id="O3" value="9.0" spread="11.24"/>
                    <measurement group_id="O4" value="5.6" spread="11.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="4.70"/>
                    <measurement group_id="O2" value="0.1" spread="5.55"/>
                    <measurement group_id="O3" value="1.4" spread="6.07"/>
                    <measurement group_id="O4" value="2.9" spread="5.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="6.05"/>
                    <measurement group_id="O2" value="-0.3" spread="6.24"/>
                    <measurement group_id="O3" value="1.2" spread="4.26"/>
                    <measurement group_id="O4" value="-1.1" spread="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="9.23"/>
                    <measurement group_id="O2" value="2.3" spread="8.57"/>
                    <measurement group_id="O3" value="3.8" spread="7.57"/>
                    <measurement group_id="O4" value="4.5" spread="5.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Pulse Rate of TID Doses for One Day of GSK2982772</title>
        <description>Pulse rate of participants were measured at indicated time points in supine position after 5 minutes rest. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
        <time_frame>Baseline (Day -1) and at 2, 7, 14, 24, 48 and 72 hours at each Treatment Period</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse Rate of TID Doses for One Day of GSK2982772</title>
          <description>Pulse rate of participants were measured at indicated time points in supine position after 5 minutes rest. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
          <population>Safety Population.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="5.35"/>
                    <measurement group_id="O2" value="1.7" spread="4.19"/>
                    <measurement group_id="O3" value="0.4" spread="4.10"/>
                    <measurement group_id="O4" value="0.8" spread="3.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="4.17"/>
                    <measurement group_id="O2" value="9.4" spread="5.60"/>
                    <measurement group_id="O3" value="8.9" spread="5.92"/>
                    <measurement group_id="O4" value="10.4" spread="6.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="3.50"/>
                    <measurement group_id="O2" value="5.3" spread="3.58"/>
                    <measurement group_id="O3" value="5.5" spread="4.44"/>
                    <measurement group_id="O4" value="8.3" spread="4.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="4.74"/>
                    <measurement group_id="O2" value="1.0" spread="3.64"/>
                    <measurement group_id="O3" value="1.1" spread="2.75"/>
                    <measurement group_id="O4" value="3.3" spread="4.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="3.98"/>
                    <measurement group_id="O2" value="1.5" spread="3.37"/>
                    <measurement group_id="O3" value="1.3" spread="4.97"/>
                    <measurement group_id="O4" value="4.3" spread="5.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="6.57"/>
                    <measurement group_id="O2" value="5.0" spread="3.79"/>
                    <measurement group_id="O3" value="2.2" spread="4.91"/>
                    <measurement group_id="O4" value="6.0" spread="5.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Body Temperature of TID Doses for One Day of GSK2982772</title>
        <description>Temperature of participants were measured at indicated time points in supine position after 5 minutes rest. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
        <time_frame>Baseline (Day -1) and at 2, 7, 14, 24, 48 and 72 hours at each Treatment Period</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Temperature of TID Doses for One Day of GSK2982772</title>
          <description>Temperature of participants were measured at indicated time points in supine position after 5 minutes rest. Baseline value was the latest pre-dose (Day -1) assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is calculated as the value at the post-dose visit minus the Baseline value.</description>
          <population>Safety Population.</population>
          <units>Degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.204"/>
                    <measurement group_id="O2" value="0.32" spread="0.199"/>
                    <measurement group_id="O3" value="0.12" spread="0.241"/>
                    <measurement group_id="O4" value="0.18" spread="0.276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.274"/>
                    <measurement group_id="O2" value="0.51" spread="0.231"/>
                    <measurement group_id="O3" value="0.43" spread="0.261"/>
                    <measurement group_id="O4" value="0.48" spread="0.366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.264"/>
                    <measurement group_id="O2" value="0.48" spread="0.191"/>
                    <measurement group_id="O3" value="0.40" spread="0.388"/>
                    <measurement group_id="O4" value="0.65" spread="0.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.223"/>
                    <measurement group_id="O2" value="-0.05" spread="0.239"/>
                    <measurement group_id="O3" value="0.08" spread="0.237"/>
                    <measurement group_id="O4" value="0.08" spread="0.286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.297"/>
                    <measurement group_id="O2" value="-0.07" spread="0.235"/>
                    <measurement group_id="O3" value="-0.08" spread="0.222"/>
                    <measurement group_id="O4" value="0.12" spread="0.292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.257"/>
                    <measurement group_id="O2" value="0.00" spread="0.191"/>
                    <measurement group_id="O3" value="0.09" spread="0.284"/>
                    <measurement group_id="O4" value="0.24" spread="0.271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Abnormal Neurological Examinations of TID Doses for One Day of GSK2982772</title>
        <description>Neurological examinations including: mental status, gait, balance, coordination, cranial nerves, motor power, reflexes, and sensory system (light touch and pain) were assessed in participants specified time points.</description>
        <time_frame>Baseline (Day -1) and at 2, 7, 14, 24, 48 and 72 hours at each Treatment Period</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O4">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Neurological Examinations of TID Doses for One Day of GSK2982772</title>
          <description>Neurological examinations including: mental status, gait, balance, coordination, cranial nerves, motor power, reflexes, and sensory system (light touch and pain) were assessed in participants specified time points.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Drug Concentration Versus Time Curve Over 24 Hours (AUC[0-24]) and AUC Over Each Dose Interval of TID Doses for One Day of GSK2982772</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24) and AUC over each dose: AUC(0-7), AUC (7-14) and AUC (14-24) after the administration of TID doses of GSK2982772. Pharmacokinetic analysis was conducted using standard non-compartmental methods. All participants in the safety population for whom a pharmacokinetic sample has been obtained and analyzed was included in the pharmacokinetic population.</description>
        <time_frame>Pre-dose, 20 and 40 minutes, 1, 1.5, 2, 3, 5, 7 hours, 7 hours 20 minutes, 7 hours 40 minutes, 8, 8.5, 9, 10, 12, 14 hours, 14 hours 20 minutes, 14 hours 40 minutes, 15, 15.5, 16, 17, 19, 22 and 24 hours post-dose at each Treatment Period</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Drug Concentration Versus Time Curve Over 24 Hours (AUC[0-24]) and AUC Over Each Dose Interval of TID Doses for One Day of GSK2982772</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24) and AUC over each dose: AUC(0-7), AUC (7-14) and AUC (14-24) after the administration of TID doses of GSK2982772. Pharmacokinetic analysis was conducted using standard non-compartmental methods. All participants in the safety population for whom a pharmacokinetic sample has been obtained and analyzed was included in the pharmacokinetic population.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
          <units>Hours*microgram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC (0-24), n=12, 12, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.153" spread="22.4"/>
                    <measurement group_id="O2" value="25.779" spread="17.7"/>
                    <measurement group_id="O3" value="54.960" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-7), TID dose 1, n=10, 10, 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.804" spread="22.4"/>
                    <measurement group_id="O2" value="6.553" spread="22.6"/>
                    <measurement group_id="O3" value="10.854" spread="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (7-14), TID dose 2, n=10, 6, 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.684" spread="18.7"/>
                    <measurement group_id="O2" value="9.200" spread="18.6"/>
                    <measurement group_id="O3" value="20.875" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (14-24), TID dose 3, n=12, 12, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.919" spread="24.9"/>
                    <measurement group_id="O2" value="10.105" spread="20.8"/>
                    <measurement group_id="O3" value="23.602" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) and Observed Trough Drug Plasma Concentrations Following Each TID Doses for One Day of GSK2982772</title>
        <description>Blood samples were collected from participants at indicated time points and analyzed for Cmax and observed trough drug plasma concentrations: C0, C7, C14 and C24 after the administration of TID doses of GSK2982772.</description>
        <time_frame>Pre-dose,20 and 40 minutes, 1, 1.5, 2, 3, 5, 7 hours,7 hours 20 minutes,7 hours 40 minutes,8, 8.5, 9, 10, 12, 14 hours,14 hours 20 minutes,14 hours40 minutes, 15, 15.5, 16, 17, 19, 22, 24, 28, 32, 36, 48, 60 and 72 hours post-dose at each Treatment Period</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) and Observed Trough Drug Plasma Concentrations Following Each TID Doses for One Day of GSK2982772</title>
          <description>Blood samples were collected from participants at indicated time points and analyzed for Cmax and observed trough drug plasma concentrations: C0, C7, C14 and C24 after the administration of TID doses of GSK2982772.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles).</population>
          <units>Micrograms per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax, TID dose 1, n=12, 12, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.187" spread="16.2"/>
                    <measurement group_id="O2" value="2.003" spread="27.7"/>
                    <measurement group_id="O3" value="3.038" spread="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, TID dose 2, n=12, 12, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.322" spread="34.2"/>
                    <measurement group_id="O2" value="2.727" spread="21.2"/>
                    <measurement group_id="O3" value="5.516" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, TID dose 3, n=12, 12, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.076" spread="32.9"/>
                    <measurement group_id="O2" value="2.378" spread="17.8"/>
                    <measurement group_id="O3" value="5.120" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C0, TID dose 1, n=0, 0, 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>C7, TID dose 1, n=12, 12, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.149" spread="55.3"/>
                    <measurement group_id="O2" value="0.344" spread="41.5"/>
                    <measurement group_id="O3" value="0.878" spread="54.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C14, TID dose 2, n=12, 12, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.175" spread="44.0"/>
                    <measurement group_id="O2" value="0.439" spread="44.6"/>
                    <measurement group_id="O3" value="0.999" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C24, TID dose 3, n=12, 12, 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.107" spread="44.7"/>
                    <measurement group_id="O2" value="0.229" spread="53.3"/>
                    <measurement group_id="O3" value="0.543" spread="47.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half Life (t1/2) After the Third TID Dose for One Day of GSK2982772</title>
        <description>Blood samples were collected from participants at indicated time points and t1/2 was analyzed after the administration of third TID dose of GSK2982772.</description>
        <time_frame>Pre-dose,20 and 40 minutes, 1, 1.5, 2, 3, 5, 7 hours,7 hours 20 minutes,7 hours 40 minutes,8, 8.5, 9, 10, 12, 14 hours,14 hours 20 minutes,14 hours40 minutes, 15, 15.5, 16, 17, 19, 22, 24, 28, 32, 36, 48, 60 and 72 hours post-dose at each Treatment Period</time_frame>
        <population>Pharmacokinetic Population. Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half Life (t1/2) After the Third TID Dose for One Day of GSK2982772</title>
          <description>Blood samples were collected from participants at indicated time points and t1/2 was analyzed after the administration of third TID dose of GSK2982772.</description>
          <population>Pharmacokinetic Population. Only those participants with data available at the specified data points were analyzed.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.883" spread="52.5"/>
                    <measurement group_id="O2" value="7.206" spread="31.9"/>
                    <measurement group_id="O3" value="6.624" spread="51.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Observed Plasma Drug Concentration (Tmax) of Each TID Doses for One Day of GSK2982772</title>
        <description>Blood samples were collected from participants at indicated time points and Tmax was analyzed after the administration of TID doses of GSK2982772.</description>
        <time_frame>Pre-dose,20 and 40 minutes, 1, 1.5, 2, 3, 5, 7 hours,7 hours 20 minutes,7 hours 40 minutes,8, 8.5, 9, 10, 12, 14 hours,14 hours 20 minutes,14 hours40 minutes, 15, 15.5, 16, 17, 19, 22, 24, 28, 32, 36, 48, 60 and 72 hours post-dose at each Treatment Period</time_frame>
        <population>Pharmacokinetic Population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2982772 60 mg</title>
            <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O2">
            <title>GSK2982772 120 mg</title>
            <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
          <group group_id="O3">
            <title>GSK2982772 240 mg</title>
            <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Plasma Drug Concentration (Tmax) of Each TID Doses for One Day of GSK2982772</title>
          <description>Blood samples were collected from participants at indicated time points and Tmax was analyzed after the administration of TID doses of GSK2982772.</description>
          <population>Pharmacokinetic Population.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TID dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.000" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="1.750" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O3" value="2.000" lower_limit="1.50" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TID dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.750" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="2.500" lower_limit="1.50" upper_limit="5.00"/>
                    <measurement group_id="O3" value="2.000" lower_limit="1.50" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TID dose 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.500" lower_limit="0.67" upper_limit="5.00"/>
                    <measurement group_id="O2" value="3.000" lower_limit="1.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="3.000" lower_limit="2.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Non-serious AEs and SAEs were collected from the start of the treatment up to 39 days</time_frame>
      <desc>Non-serious AEs and SAEs were collected for Safety population</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants were administered PBO matching GSK2982772 via oral route using a 7 hours dosing interval in each TP</description>
        </group>
        <group group_id="E2">
          <title>GSK2982772 60 mg</title>
          <description>Participants were administered GSK2982772 60 mg via oral route using a 7 hours dosing interval in each TP</description>
        </group>
        <group group_id="E3">
          <title>GSK2982772 120 mg</title>
          <description>Participants were administered GSK2982772 120 mg via oral route using a 7 hours dosing interval in each TP</description>
        </group>
        <group group_id="E4">
          <title>GSK2982772 240 mg</title>
          <description>Participants were administered GSK2982772 240 mg via oral route using a 7 hours dosing interval in each TP</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

